Understanding PCSK9 and anti-PCSK9 therapies

Journal of Clinical Lipidology

Volumn 9, Issue 2, 2015, Pages 170-186

  McKenney, James M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Atherosclerotic cardiovascular disease; Dyslipidemia; LDL receptors Statins; Monoclonal antibody; Proprotein convertase subtilisin kexin type 9 (PCSK9)

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 MONOCLONAL ANTIBODY; SERINE PROTEINASE; TRANSCRIPTION FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL; PCSK9 PROTEIN, HUMAN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFORMATION; HUMAN; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; DYSLIPIDEMIAS; GENETICS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; CHOLESTEROL; DYSLIPIDEMIAS; HUMANS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84928814587     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.01.001     Document Type: Review

References (68)

1. N.G. Seidah, S. Benjannet, and L. Wickham The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc Natl Acad Sci U S A 100 2003 928 933
2. S. Benjannet, D. Rhainds, and R. Essalmani NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein LDL) receptor and LDL cholesterol J Biol Chem 279 2004 48865 48875
3. D. Cunningham, D.E. Danley, and K.F. Geoghegan Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nat Struct Mol Biol 14 2007 413 419
4. N.G. Seidah, Z. Awan, M. Chretien, and M. Mbikay PCSK9: A key modulator of cardiovascular health Circ Res 114 2014 1022 1036
5. A. Zaid, A. Roubtsova, and R. Essalmani Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role of mouse liver regeneration Hepatology 48 2008 646 654
6. S. Rashid, D.E. Curtis, and R. Garuti Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9 Proc Natl Acad Sci U S A 102 2005 5374 5379
7. B. Dong, M. Wu, and H. Li Strong induction of PCSKi9 gene expression through HNF1alpha and SREBP2: mechanisms for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters J Lipid Res 51 2010 1486 1495
8. H.J. Jeong, H.S. Lee, K.S. Kim, D. Yoon, and S.W. Park Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 J Lipid Res 49 2008 390 409
9. H. Li, B. Dong, S.W. Park, H.S. Lee, W. Chen, and J. Liu Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine J Biol Chem 284 2009 28885 28895
10. D.W. Zhang, T.A. Lagace, and R. Garuti Binding of pro-protein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation J Biol Chem 282 2007 18602 18612
11. M.J. Bottomley, A. Cirillo, and I. Orsatti Structural and biochemical characterization of the wild type PCSK9/EGF (AB) complex and natural familial hypercholesterolemia mutants J Biol Chem 284 2009 1313 1323
12. P.L. Surdo, M.J. Bottomley, and A. Calzetta Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH EMBO Rep 12 2011 1300 1305
13. E.M. Roth, M.R. Taskinen, and H.N. Ginsberg Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial Int J Cardiol 176 2014 55 61
14. M.J. Koren, P.L. Lundqvist, M. Bolognese for the MENDEL-2 Investigators Anti-PCSK9 monotherapy for hypercholesterolemia - the MENDEL-2 randomized, controlled phase 3 clinical trial of evolocumab JACC 63 2014 2531 2540
15. J. Mayne, T. Dewpura, and A. Raymond Plasma PCSK9 levels are significantly modified by statins and fibrates in humans Lipids Health Dis 7 2008 22
16. H.E. Careskey, R.A. Davis, W.E. Alborn, J.S. Troutt, G. Cao, and R.J. Konrad Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9 J Lipid Res 49 2008 394 398
17. G. Welder, I. Zineh, M.A. Pacanowski, J.S. Troutt, G. Cao, and R.J. Konrad High- dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol J Lipid Res 51 2010 2714 2721
18. Z. Awan, N.G. Seidah, and J.G. Macfadyen Rosuvastatin, proprotein convertase subtilisin/kexin 9 concentrations, and LDL cholesterol response: the JUPITER trial Clin Chem 58 2012 183 189
19. G. Dubuc, M. Tremblay, and G. Pare A new method of measurement of total plasma PCSK9: clinical applications J Lipid Res 51 2010 140 149
20. E.A. Stein, S. Mellis, and G.D. Yancopoulos Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 2012 1108 1118
21. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy JACC 59 2012 2344 2353
22. R.P. Giugliano, N.R. Desai, P. Kohli for the LAPLACE-TIMI 57 Investigators Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study Lancet 380 2012 2007 2017 (and supplementary appendix)
23. K. Tveten, O.L. Holla, and J. Cameron Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification Hum Mol Genet 21 2012 1402 1409
24. S. Poirier, G. Mayer, and V. Poupon Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route J Biol Chem 284 2009 28856 28864
25. T.A. Lagace, D.E. Curtis, and R. Garuti Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice J Clin Invest 116 2006 2995 3005
26. A. Grefhorst, M.C. McNutt, T.A. Lagace, and J.D. Horton Plasma PCSK9 preferentially reduces liver receptors in mice J Lipid Res 49 2008 1303 1311
27. Y. Luo, L. Warren, and D. Xia Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice J Lipid Res 50 2009 1581 1588
28. M. Liu, G. Wu, and J. Baysarowich PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain J Lipid Res 51 2010 2611 2618
29. E. Rousselet, J. Marcinkiewicz, and J. Kriz PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke J Lipid Res 52 2011 1383 1391
30. G. Lambert, F. Charlton, K.A. Rye, and D.E. Piper Molecular basis of PCSK9 function Atherosclerosis 203 2009 1 7
31. G. Tibolla, G.D. Norata, R. Artali, F. Meneghetti, and A.L. Catapano Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure:function relation to therapeutic inhibition Nutr Metab Cardiovasc Dis 21 2011 835 843
32. S.G. Lakoski, T.A. Lagace, J.C. Cohen, J.D. Horton, and H.H. Hobbs Genetic and metabolic determinants of plasma PCSK9 levels J Clin Endocrinol Metab 94 2009 2537 2543
33. L. Persson, G. Cao, and L. Stahle Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans Arterioscler Thromb Vasc Biol 30 2010 2666 2672
34. V.M. Homer, A.D. Marais, and F. Charlton Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa Atherosclerosis 196 2008 659 666
35. M.C. McNutt, H.J. Kwon, C. Chen, J.R. Chen, J.D. Horton, and T.A. Lagace Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells J Biol Chem 284 2009 10561 10570
36. S. Pandit, D. Wisniewski, and J.C. Santoro Functional analysis of sites within PCSK9 responsible for hypercholesterolemia J Lipid Res 49 2008 1333 1345
37. S. Poirier, and G. Mayer The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol Drug Des Devel Ther 7 2013 1135 1145
38. S.E. Humphries, R.A. Whittall, C.S. Hubbart for the Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee Genetic causes of familial hypercholesterolemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk J Med Genet 43 2006 943 949
39. J.C. Cohen, E. Boerwinkle, T.G. Mosley Jr., and H.H. Hobbs Sequence variation in PCSK9, low LDL, and protection against coronary heart disease NEJM 354 2006 1264 1272
40. J.H. Amanda, A.D. Marais, D.M. Tanyanyiwa, and J.R. Burnett The C676X mutation in PCSK9 is present and lowers cholesterol in a southern African population Atherosclerosis 193 2007 445 448
41. B. Cariou, K. Ouguerram, and Y. Zair PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia Arterioscler Thromb Vasc Biol 29 2009 2192 2197
42. Z. Zhao, Y. Tuakli-Wosornu, and T.A. Lagace Molecular characteristics of loss-of-function mutations in PCSK9 and identification of compound heterozygote Am J Hum Genet 79 2006 514 523
43. M.K. Montgomery, S. Xu, and A. Fire RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans Proc Natl Acad Sci U S A 95 1998 15502 15507
44. K. Fitzgerald, M. Frank-Kamentsky, and S. Shulga-Morskaya Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial Lancet 383 2014 60 68
45. Available at: clinicaltrials.gov. Accessed March 12, 2015.
46. S. Shi Biologics: an update and challenge of their pharmacokinetics Curr Drug Metab 15 2014 271 290
47. E. Roth, J.M. McKenney, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 2012 1891 1900
48. D.J. Blom, T. Hala, M. Bolognese DESCARTES Investigators A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
49. H.H. Hobbs, M.S. Brown, and J.L. Goldstein Molecular genetics of the LDL receptor gene in familial hypercholesterolemia Hum Mutat 1 1992 445 466
50. E.A. Stein, N. Honarpour, S.M. Wasserman, F. Xu, R. Scott, and F.J. Raal Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia Circulation 128 2013 2113 2120
51. F.J. Raal, N. Honarpour, D.J. Blom for the TESLA Investigators Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 2014 [Epub ahead of print]
52. F.J. Raal, E.A. Stein, R. Dufour for the RUTHERFORD-2 Investigators PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 2014 [Epub ahead of print]
53. Kastelein JJP, Ginsberg HN, Langslet G, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia (heFH) not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. Presented at the European Society of Cardiology Congress 2014, Barcelona (August 30, 2014).
54. E. Stroes, D. Colquhoun, D. Sullivan GAUSS-2 Investigators Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
55. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: Efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and statin rechallenge arm. Presented at the American Heart Association Scientific Session 2014, Chicago (Nov 20, 2014).
56. J.G. Robinson, B.S. Nedergaard, W.J. Rogers LAPLACE-2 Investigators Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 2014 1870 1882
57. D.J. Kereiakes, J.G. Robinson, and C.P. Cannon Efficacy and safety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I study Am Heart J 2015 [epub ahead of print]
58. C.P. Cannon, B. Cariou, and D. Blom Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Eur Heart J 2015 [epub ahead of print]
59. B.G. Nordestgaard, M.J. Chapman, S.E. Humphries European Atherosclerosis Society Consensus Panel Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society Eur Heart J 34 2013 3478 3490a
60. E.A. Stein, D. Gipe, and J. Bergeron Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 2012 29 36
61. F. Raal, R. Scott, and R. Somaratne Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
62. E.A. Stein, K. Strutt, H. Southworth, P.J. Diggle, E. Miller HeFH Study Group Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia Am J Cardiol 92 2003 1287 1293
63. H. Zhang, J. Plutzky, and S. Skentzos Discontinuation of statins in routine care settings: a cohort study Ann Intern Med 158 2013 526 534
64. J.M. McKenney, P.H. Jones, M.A. Adamczyk, V.A. Cain, B.S. Bryzinski, J.W. Blasetto STELLAR Study Group Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial Curr Med Res Opin 19 2003 689 698
65. M.S. Sabatine, R.P. Giugliano, and S.D. Wiviott Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 2015 [epub ahead of print]
66. J.G. Robinson, M. Farnier, and M. Krempf Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 2015 [epub ahead of print]
67. M.J. Koren, R.P. Giugliano, F.J. Raal OSLER Investigators Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial Circulation 129 2014 234 243
68. G. Schonfeld Familial hypobetalipoproteinemia: a review J Lipid Res 44 2003 878 883